Add to ORKGABSTRACT: Obesity and metabolic syndrome in association with an increased risk of cardiovascular disease and type II diabetes are significant problems that contribute to lower life expectancy of patients with schizophrenia. Understanding the pharmacological mechanisms of the current antipsychotic treatment is clearly the key to the improvement of pharmacotherapy, to avoid or to mitigate the metabolic adverse effects. KEY WORDS: antipsychotic, pharmacological mechanisms, metabolic disorders
Patients affected by psychotic disorders are more likely to develop high rates of co-morbidities, su...
Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease and type II d...
Metabolic syndrome has been associated with schizophrenia since long before the era of antipsychotic...
Abstract: Important sources of metabolic diseases such as obesity and metabolic syndrome are signifi...
BACKGROUND: Cardiovascular morbidity and mortality are higher in patients with schizophrenia than in...
BACKGROUND: Cardiovascular morbidity and mortality are higher in patients with schizophrenia than in...
BACKGROUND: Cardiovascular morbidity and mortality are higher in patients with schizophrenia than in...
BACKGROUND: Cardiovascular morbidity and mortality are higher in patients with schizophrenia than in...
The increase in cardiovascular disease and reduced life expectancy in schizophrenia likely relate to...
Objectives: To review current evidence for the hypothesis that treatment with antipsychotic medicati...
Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as obesity, hy...
Schizophrenia is associated with an increased risk of metabolic disorders such as diabetes, dyslipid...
none3noMetabolic syndrome is a complex pathology characterized by imbalances in lipid and glucose me...
Metabolic syndrome and other cardiovascular risk factors are highly prevalent in people with schizop...
Patients affected by psychotic disorders are more likely to develop high rates of co-morbidities, su...
Patients affected by psychotic disorders are more likely to develop high rates of co-morbidities, su...
Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease and type II d...
Metabolic syndrome has been associated with schizophrenia since long before the era of antipsychotic...
Abstract: Important sources of metabolic diseases such as obesity and metabolic syndrome are signifi...
BACKGROUND: Cardiovascular morbidity and mortality are higher in patients with schizophrenia than in...
BACKGROUND: Cardiovascular morbidity and mortality are higher in patients with schizophrenia than in...
BACKGROUND: Cardiovascular morbidity and mortality are higher in patients with schizophrenia than in...
BACKGROUND: Cardiovascular morbidity and mortality are higher in patients with schizophrenia than in...
The increase in cardiovascular disease and reduced life expectancy in schizophrenia likely relate to...
Objectives: To review current evidence for the hypothesis that treatment with antipsychotic medicati...
Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as obesity, hy...
Schizophrenia is associated with an increased risk of metabolic disorders such as diabetes, dyslipid...
none3noMetabolic syndrome is a complex pathology characterized by imbalances in lipid and glucose me...
Metabolic syndrome and other cardiovascular risk factors are highly prevalent in people with schizop...
Patients affected by psychotic disorders are more likely to develop high rates of co-morbidities, su...
Patients affected by psychotic disorders are more likely to develop high rates of co-morbidities, su...
Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease and type II d...
Metabolic syndrome has been associated with schizophrenia since long before the era of antipsychotic...